ET-101 is a novel therapeutic antibody, currently under investigation for the inhibition of the growth of cancer stem cells.
Under the deal, Lonza will produce phase 1 clinical material at its mammalian development and manufacturing facility in Slough, UK.
Eclipse Therapeutics CSO Christopher Reyes said Lonza’s antibody manufacturing capabilities will support the development strategy to deliver the effective therapeutics targeting cancer stem cells.
Eclipse Therapeutics is a private biotechnology company focused on the discovery and development of therapeutics that target cancer stem cells and other forms of innovative cancer treatment.